JCOG

The Japan Clinical Oncology Group (JCOG) is the largest Japanese cooperative group funded primarily by the National Cancer Center Research and Development Fund.

JEOG:Japan Esophageal Oncology Group / Publications

更新日:2011年9月12日

a. 論文

1. 委員会承認の治療研究

JCOG8201
T Iizuka, H Ide, T Kakegawa, et al.: Preoperative Radioactive Therapy for Esophageal Carcinoma: Randomized Evaluation Trial in Eight Institutions. Chest. 3: 1054-1058, 1988.
JCOG8503
Japanese Esophageal Oncology Group: A Comparison of Chemotherapy and Radiotherapy as Adjuvant Treatment to Surgery for Esophageal Carcinoma. Chest. 104: 203-207, 1993.
JCOG8703
T Iizuka, T Kakegawa, H Ide, et al.: Phase II Evaluation of Combined Cisplatin and Vindesine in Advanced Squamous Cell Carcinoma of the Esophagus: Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol. 21(3) : 176-179, 1991.
JCOG8806
N Ando, T Iizuka, T Kakegawa, et al.: A Randomized Trial of Surgery with and without Chemotherapy for Localized Squamous Carcinoma of the Thoracic Esophagus: The Japan Clinical Oncology Group Study. J Thorac Cardiovasc Surg. 114: 205-209, 1997.
JCOG8807
T Iizuka, T Kakegawa, H Ide, et al.: Phase II Evaluation of Cisplatin and 5-Fluorouracil in Advanced Squamous Cell Carcinoma of the Esophagus: A Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol. 22(3) : 172-176, 1992.
JCOG9204
N Ando, T Iizuka, H Ide, et al : Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: A Japan ClinicalOncology Group Study ?JCOG 9204. J Clin Oncol. 21:4592-4596, 2003
JCOG9407
K Hayashi, N Ando, H Watanabe, et al.: Phase II Evaluation of Protracted Infusion of Cisplatin and 5-Fluorouracil in Advanced Squamous Cell Carcinoma of the Esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol. 31(9) :419-423, 2001.
JCOG 9516
K Ishida, N Ando, S Yamamoto, et al.: Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus : a Japan Esophageal Oncology Group (JEOG)/ Japan Clinical Oncology Group trial (JCOG9516): Jpn J Clin Oncol 34(10):1-5, 2004.
JCOG 9708
H Kato, A Sato, H Fukuda, et al.: A Phase II Trial of Chemoradiotherapy for Stage I Esophageal Squamous Cell Carcinoma: Japan Clinical Oncology Group Study (JCOG9708). Jpn J Clin Oncol. 39:638-643, 2009.
JCOG 9907
N Ando, H Kato, H Igaki, et al.: A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-fluorouracil versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907). Ann Surg Oncol. Online First August 2011.
M. Hirao, N. Ando, T. Tsujinaka, et al.: Influence of preoperative chemotherapy for advanced thoracic oesophageal squamous cell carcinoma on perioperative complications. Br J Surg. DOI: 10.1002/bjs.7683 September 2011.
JCOG0303
N Sanuki, S Ishikura, M Shinoda, et al.: Radiotherapy Quality Assurance Review for A Multi-center Randomized Trial of Locally Advanced Esophageal Cancer: The Japan Clinical Oncology Group (JCOG) Trial 0303. Int J Clin Oncol. DOI:10.1007/s10147-011-0264-9,2011.

2. グループ代表者管理の治療研究

なし    

3. 附随研究等

  • K Ishida, T Iizuka, N Ando, et al.: Phase II Study of Chemotherapy for Advanced Squamous Cell Carcinoma of the Thoracic Esophagus: Nine Japanese Institutions Trial. Jpn J Clin Oncol. 26: 310-315, 1996.
  • T Nishimaki, O Tanaka, N Ando, et al.: Evaluation of the Accuracy of Preoperative Staging in Thoracic Esophageal Cancer. Ann Thorac Surg. 68: 2059-2064, 1999.

4. 総説・解説

  • 安藤暢敏:進行食道癌に対する集学的治療. 日消外会誌. 314:138-142, 1998.
  • 安藤暢敏:術前化学放射線療法. 消化器病セミナー. 80:53-61, 2000.
  • 安藤暢敏、石 志紘:食道癌の化学療法. 日消外会誌. 103:359-363, 2002.
  • 安藤暢敏:切除可能食道癌の手術補助療法-有効か否か-. 臨床外科. 57:199-203, 2002.
  • T Kodaira, N Fuwa, M Shinoda, et al : Multivariate analysis of treatment outcome in patients with esophageal carcinoma treated with definitive radiotherapy. Am J Clin Oncol. 26:392-397, 2003.
  • H Takeuchi, S Ozawa, N Ando, et al : Cell-cycle regulators and the Ki-67 labeling index can predict the response to chemoradio- therapy and the survival of patients with locally advanced squamous cell carcinoma of the esophagus. Ann Surg Oncol. 10:792-800, 2003.
  • Y Kinoshita, H Udagawa, K Tsutsumi, et al : Esophageal carcinoma with tracheal stenosisdue to tumor invasion and long survival after chemoradiotherapy. Diseases of the Esophagus 16:261-264, 2003.
  • Y Doki, O Ishikawa, T Kabuto,et al : Possible indication for surgical treatment of squamous cell carcinomas of the esophagus that involve the stomach. Surgery 133: 479-485, 2003.
  • S Ishikura, K Nihei, A Ohtsu, et al : Long-termtoxicity after definitive chemo-radiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol. 21:2697-2702, 2003.
  • 安藤暢敏 :癌治療適応のパラダイムシフト -手術から非手術へー.日医雑誌 130:1015-1019, 2003.
  • 室 圭、新井達広、加藤抱一、他:食道癌に対する根治的な放射線化学療法.臨床消化器内科. 18:1507-1514, 2003.
  • 中村 努、井手博子、江口礼紀、他:進行食道癌に対するNedaplatin+5-FU化学放射線療法の治療成績.癌と化学療法. 30:803-807, 2003.
  • 宇田川晴司、堤 謙二、上野正紀、他:切除断端陽性が疑われる食道癌に対する術前化学放射線療法の評価.日本外科系連合学会誌. 28:690-697, 2003 .
  • 松原久裕、落合武徳:外科におけるランダム化比較試験 (RCT)の問題点.外科. 65:1004-1010, 2003.
  • 石倉 聡:放射線治療の多施設共同研究におけるquality assuranceとquality control.血液・腫瘍科. 47: 388-392, 2003.
  • 梶山美明、鶴丸昌彦、岩沼佳見、他:食道癌治療のControversy -外科の立場からー.癌と化学療法. 30:1225-1229, 2003.
  • 佐藤道夫、安藤暢敏:進行食道癌に対する化学療法. 外科 66(11): 1254-1258, 2004.
  • H Igaki, Y Tachimori, H Kato.: Improved survival for patients with upper and/ or middle mediastinal lymph node metastasis of squamous cell carcinoma of the lower thoracic esophagus treated with 3-field dissection. Ann Surg. 239:483-490, 2004.
  • 山名秀明:食道がんに対する術後補助化学療法の有効性. 血液・腫瘍科. 49(3):311-316, 2004.
  • T Nakamura, et al.: Salvage esophagectomy after definitive chemotherapy and radiotherapy for advanced esophageal cancer. Am J Surg 188:261-266, 2004.
  • M Hirao, T Tsujinaka, et al.: Phase I study of the combination of nedaplatin, adriamycin and 5-fluorouracil for treatment of advanced esophageal cancer. Dis Esophagus 17(3): 247-250, 2004.
  • 安藤暢敏:がん治療のcontroversy 1)食道がんの治療選択:化学放射線療法 vs.外科的切除.臨床腫瘍内科学入門 332-336, 2005
  • 佐藤道夫、安藤暢敏:食道癌治療の最前線 術前術後の化学療法.消化器病セミナー 99:85-95, 2005
  • H Fujita, S Sueyoshi, H Yamana, et al.: Esophagectomy:Is it Necessary after Chemoradiotherapy for a Locally Advanced T4 Esophageal Cancer?Prospective Nonrandomized Trial Comparing Chemoradiotherapy with Surgery versus without Surgery. World J Surg 29 : 25-31, 2005.
  • T Nakamura, K Hayashi, M Ota, et al.: Salvage surgery after definitive chemoradiotherapy for esophageal cancer. Esophagus 2 : 123-128, 2005.
  • 三浦 昭順、永井 鑑、河野 辰幸、他:進行・再発食道癌に対するsecond-lineとしての Docetaxel + Nedaplatin併用療法の検討. 日気食会報 56 : 336-342, 2005
  • M Yano, T Yasuda, H Miyata, et al.: Correlation Between Histological Effects on the Main Tumors and Nodal Status after Chemoradiotherapy for Squamous Cell Carcinoma of the Esophagus. J Surg Oncol 89 : 244-250, 2005
  • S Kosugi, T Kanda, S Nakagawa, et al.: Efficacy and toxicity of fluorouracil, doxorubicin, and cisplatin/ nedaplatin treatment as neoadjuvant chemotherapy for advanced esophageal carcinoma. Scand J Gastroenterol 40 : 886-892, 2005.
  • 平尾基宏、藤谷和正、辻仲利政、他:根治切除不能進行食道癌に対するNedaplatin/Adriamycin/5-FU(NAF)併用療法のPhase I Study. Jpn J Cancer Chemother 32 : 53-56, 2005.
  • M Shinoda, S Hatooka, S Mori, et al : Clinical Aspects of Multimodality Therapy for Resectable Locoregional Esophageal Cancer. Ann Thorac Cardiovasc Surg 12:234-241, 2006.
  • T Nakamura, M Ota, K Hayashi, et al:Chemoradiotherapy With and Without Esophagectomy for Advanced Esophageal Cancer. Hepato-Gastroenterology 53:705-709, 2006.
  • Y Tomimaru, M Yano, K Takachi, et al : Factors affecting the prognosis of patients with esophageal cancer undergoing salvage surgery after definitive chemoradiotherapy. J Surg Oncol 93:422-428, 2006.
  • A Ashida, N Boku, K Aoyagi, et al : Expression profiling of esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy: clinical implications. Int J Oncol 28:1345-1352, 2006.
  • T Suwa, Y Kitagawa, T Sasaki, et al : Release of band cells from the bone marrow is impaired by preoperative chemoradiation in patients with esophageal carcinoma: increased risk of postoperative pneumonia. Langenbecks Arch Surg 391:461-466, 2006.
  • S Kosugi, T Kanda, T Nishimaki, et al : Successful treatment for esophageal carcinoma with lung metastasis by induction chemotherapyfollowed by salvage esophagectomy: Report of a case. World J Gastroenterol 12:4101-4103, 2006.
  • Y To, T Ohga, S Ito, et al: radical surgery and definitive chemoradiotherapy for patients with submucosal esophageal squamous cell carcinomas. Anticancer Res 26:2487-2491, 2006.
  • N Ando : Postoperative adjuvant therapy for completely resected esophageal cancer. Difficult Decisions in Thoracic Surgery An Evidence-Based Approach (M Ferguson Ed.) 265-270, Springer 2007.
  • 南出純二、青山法夫、高田 賢、他:食道癌に対するSecond-Line ChemotherapyとしてのCisplatin、5-FU、Docetaxel併用療法の検討.癌と化学療法 34:49-52, 2007.
  • H Yamana, T Tanaka, H Fujita, et al:Second-Line Combination Chemotherapy with Docetaxel for Clisplatin-Pretreated Refractory Metastatic Esophageal Cancer:A Preliminary Report of Initial Experience. Chemotherapy.53:449-453,2007.
  • 中村 努、大田正穂、 成宮孝祐、他:予後よりみた食道癌に対する化学放射線療法後salvage手術の適応.癌の臨床.53(10):619-623,2007.
  • H Matsubara :Salvage surgery for esophageal carcinoma after definitive chemoradiation therapy. Ann Thorac Cardiovasc Surgery.13(5):293 - 295,2007.
  • T Uno, K Isobe, H Mastubara, et al.:Concurrent chemoradiation for patients with squamous cell carcinoma of the cervical esophagus. Dis Esophagus.20(1):12-18,2007.
  • M Kanai, S Mastumoto, G Watanabe, et al.:Retrospective analysis of 27 consecutive patients treated with docetaxel/nedaplatin combination therapy as a second-line regimen for advanced esophageal cancer. Int J Clin Oncol. 12(3):224-227,2007.
  • S Takeuchi, A Ohtsu, K Minashi, et al.:A Retrospective Study of Definitive Chemoradiotherapy for Elderly Patients With Esophageal Cancer. Am J of Clin Oncol.30(6):607-611,2007.
  • 竹内 裕也、北川 雄光、安藤 暢敏、他:胸部食道癌に対する根治的化学放射線療法後salvage手術の検討.癌の臨床. 53(10):599-604,2007.
  • T Tanabe, T Kanda, Kosugi S, et al.:Extranodal Spreading of Esophageal Squamous Cell Carcinoma:Clinicopathological Characteristics and Prognostic Impact. World J Surg.31:2192-2198,2007.
  • 佐藤 弘、坪佐 恭宏、朴 成和、他:胸部食道癌に対する根治目的放射線化学療法後のsalvage手術の意義と適応について.癌の臨床.53(10):635-639,2007.
  • T Shiratori, S Okazumi, H Matsubara, et al.:Have surgical outcomes of pathologic T4 esophageal squamous cell carcinoma really improved? Analysis of 268 cases during 45 years of experience. J Am Coll Surg.206(1):48-56,2008.
  • T Nakajima, T Ura, Y Ito, et al.: A Phase I Trial of 5-fluorouracil with Cisplatin and Concurrent Standard-dose Radiotherapy in Japanese Patients with Stage II/III Esophageal Cancer. Jpn J Clin Oncol. 39: 37-42, 2009.
  • H Akita, Y Doki, M Yano, et al.: Effects of neoadjuvant chemotherapy on primary tumor and lymph node metastasis in esophageal squamous cell carcinoma: additive association with prognosis. Dis Esophagus. 22: 291-7, 2009.
  • M Yano, M Motoori, K Tanaka, et al.: Assessment of neoadjuvant chemotherapy for patients with advanced squamous cell carcinoma of the esophagus. Esophagus. 6: 111-6, 2009.
  • S Yamamoto, R Ishihara, M Motoori, et al.: Endoscopic classification of local recurrence after definitive chemoradiotherapy for esophageal squamous cell carcinoma. Esophagus. 6: 243-8, 2009
  • Y Akutsu, H Matsubara, K Shuto, et al.: Clinical and pathologic evaluation of the effectiveness of neoadjuvant chemoradiation therapy in advanced esophageal cancer patients. World J Surg. 33: 1002-9, 2009.
  • R Ishihara, S Yamamoto, H Iishi, et al.: Factors predictive of tumor recurrence and survival after initial complete response of esophageal squamous cell carcinoma to definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys. 76: 123-9, 2010.
  • S Yamamoto , R Ishihara , M Motoori , et al.: Comparison between definitive chemoradiotherapy and esophagectomy in patients with clinical stage I esophageal squamous cell carcinoma. Am J Gastroenterol . 106(6): 1048-1054, 2011.
  • M Motoori, M Yano, T Yasuda, et al.: Chemotherapy-induced toxicities and treatment efficacy in advanced esophageal cancer treated with neoadjuvant chemotherapy followed by surgery. Esophagus. 8:81-87,2011.
  • R Ishihara, S Yamamoto, H Iishi, et al: Predicting the effects of chemoradiotherapy for squamous cell carcinoma of the esophagus by induction chemotherapy response assessed by positron emission tomography: toward PET-response-guided selection of chemoradiotherapy or esophagectomy. Int J Clin Oncol . 2011 Jul 8. [Epub ahead of print]

b. 主な学会発表

1. 委員会承認の治療研究

JCOG8806
N Ando, T Iizuka, T Kakegawa, et al.: A Randomized Trial Comparing Surgery to Surgery plus Postoperative Chemotherapy for Localized Squamous Carcinoma of the Thoracic Esophagus: The Japan Clinical Oncology Group Study. The 34th Annual Meeting of the American Society of Clinical Oncology. May 1998.
JCOG9204
N Ando, T Iizuka, H Ide, et al.: A randomized trial of surgery alone vs surgery plus postoperative chemotherapy with cisplatin and 5-fluorouracil for localized squamous carcinoma of the thoracic esophagus: The Japan Clinical Oncology Group Study (JCOG9204). The 35th Annual Meeting of the American Society of Clinical Oncology. May 1999.
JCOG9905-DI
K Muro, N Ando, T Nishimaki, et al.: A phase II study of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus: The Japan Clinical Oncology Group (JCOG) trial (JCOG 9905). The 39 Annual Meeting of the American Society of Clinical Oncology. May 2003.
JCOG9708
加藤抱一、山名秀明、宇田川晴司、他:ワークショップ9「食道sm癌の治療戦略」:Stage I 食道がんに対する放射線・抗がん剤同時併用療法の有用性. 第40回日本癌治療学会. 2002年10月.
H Kato, H Udagawa, A Togo et al.: A phase II trial of chemo-radiotherapy in patients with stage I esophageal squamous cell carcinoma: The Japan Clinical Oncology Group study (JCOG 9905). The 39 Annual Meeting of the American Society of Clinical Oncology. May 2003.
JCOG9907
N Ando, H. Kato, M. Shinoda, et al.:A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for localized squamous cell carcinoma of the thoracic esophagus (JCOG 9907).Gastrointestinal Cancer Symposium.2008.
H. Igaki, H. Kato, N Ando, et al.:A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage II/III squamous cell carcinoma of the thoracic esophagus (JCOG 9907).ASCO Annual Meeting.2008.
JCOG0303
M. Shinoda, N Ando, H. Kato, et al.:A multicenter randomized phase II (rPII)/ III study comparing concurrent chemoradiotherapy (CRT) with low-dose cisplatin plus continuous infusion of 5-fluorouracil (LDPF) and standard-dose PF (SDPF) for locally advanced unresectable squamous cell carcinoma of the thoracic esophagus (JCOG0303). The 46 Annual Meeting of the American Society of Clinical Oncology. May 2010.
篠田雅幸,安藤暢敏,石倉 聡,他:食道がんを対象とした多施設共同研究の課題-JCOG0303を通して-.第64回日本食道学会学術集会,2010.
S Ishikura, M Shinoda, K Nakamura, et al.: Patterns of failure after definitive chemoradiotherapy for unresectable carcinoma of the thoracic esophagus: Secondary analyses of the Japan Clinical Oncology Group (JCOG) 0303 trial. The 53rd ASTRO Annual Meeting, 2011.
JCOG0807
広中秀一、坪佐恭宏、浜本康夫、他:切除不能/再発食道癌に対するDCF療法の臨床第I/II相試験(JCOG0807).第64回 日本食道学会学術集会. 2010年8月.
その他
N Ando, T Iizuka, T Kakegawa, et al.: A randomized trial of surgery with and without chemotherapy for localized squamous cell carcinoma of the thoracic esophagus: JCOG study. The 7th World Congress of the International Society for Diseases of the Esophagus. Sep 1998.
安藤暢敏、飯塚紀文、井手博子、他:ワークショップ:外科における癌化学・免疫療法 ―state of the art― 食道癌に対する術後補助化学療法の再発予防効果 -JCOG Study― . 第100回日本外科学会総会. 2000年4月.
N Ando: Multimodality treatment, Perspective. The 8th World Congress of the International Society for Diseases of the Esophagus. Sep 2001.
H Udagawa, K Tsutsumi, Y Kinoshita, et al.: Evaluation of the efficacy of preoperative chemoradiotherapy to resectable esophageal cancer with suspicious positive surgical margin (cT4'). 9th ISDE INTERNATIONAL SOCIETY FOR DSEASES OF THE ESOPHAGUS, May 2004.
松原久裕、浦島哲郎、岡住慎一、他:パネルディスカッション「食道癌に対する集学的治療」:個別化治療をめざした食道癌に対する集学的治療. 第66回日本臨床外科学会総会. 2004年10月.
安藤暢敏:教育セッション 食道癌.第45回日本癌治療学会総会

2. グループ代表者管理の治療研究

なし  

3. 附随研究等

なし  

4. 総説・解説

  • N Ando: Lymphadenectomy for esophageal cancer - Multidisciplinary therapy - wher does it fit? 10th ISDE INTERNATIONAL SOCIETY FOR DSEASES OF THE ESOPHAGUS 2 . Adelaide, Feb 2006 .
  • 安藤暢敏:教育講演「食道癌治療の現状と展望 -State of the Art-」第43回日本癌治療学会総会 2005年10月.